Company news
ABVC BioPharma, Inc. news in 2025
ABVC BioPharma, Inc.'s news releases, calls and decks from 2025, newest first.
ABVC BioPharma Highlights Safety Profile of Its Plant-Based ADHD Candidate Amid Growing Concerns About Psychiatric Polypharmacy in the United States
December 2, 2025
ABVC BioPharma Highlights Strengthened Operations at BioKey's 28,176-sq.-ft. Silicon Valley Facility, Featuring U.S.-Based Multi-Product Capabilities Including Functional Foods, and Expansion Outlook Supporting Up to [1,000] Jobs by 2030
November 26, 2025
ABVC Receives US$250,000 From ForSeeCon; Vitargus(R) Total Licensing Fee up to US$33.5 Million; US$816,000 Already Received
November 21, 2025
ABVC BioPharma Receives US$240,000 Licensing Payment From OncoX BioPharma; Total Licensing Payments Reach Approximately US$2.53 Million
November 18, 2025
ABVC BioPharma Reports 230% YoY Licensing Revenue Growth and 181% Asset Expansion in Q3 2025
November 3, 2025
ABVC BioPharma Receives Additional US$100,000 Licensing Payment from OncoX BioPharma, Bringing Total Payments to US$695,950
October 31, 2025
ABVC BioPharma Highlighted by U.S. Financial Media as One of the Best Biotech Investments; Q3 Licensing Revenue Reaches $1.27 Million, With Clear Clinical Progress Across CNS and Oncology
October 17, 2025
ABVC BioPharma Has Received a Cumulative Total of US$566,000 Under ForSeeCon Licensing Agreement Supporting GMP Facility in Hsinchu for Vitargus(R) Production
October 8, 2025
ABVC BioPharma Reports US$1.03 Million in Total Licensing Revenues Collected in Q3 to Date, Highlighting High-Margin Business Model
September 19, 2025
ABVC BioPharma Receives $450,000 in Licensing Payments From OncoX BioPharma in Q3 2025
August 29, 2025
BioLite, Inc., an ABVC BioPharma Subsidiary, Receives $230,000 Milestone Payment from AiBtl, Advancing Botanical Drug Licensing Collaboration
August 27, 2025
ABVC BioPharma Receives $100,000 Milestone Payment From ForSeeCon, Strengthening Vitargus(R) Licensing Deal
August 22, 2025
ABVC BioPharma, Inc. Reports 103% Year-Over-Year Asset Growth and Secures $350K in Post-Quarter Licensing Revenue in Q2 2025
August 14, 2025
BioKey Stands as a Strategic U.S. Pharmaceutical Platform Amid Global Tariff Shifts
August 8, 2025
ABVC BioPharma Gains Confidence From International Investors to Support Growth Path
August 6, 2025
OncoX Deepens ABVC Alliance
August 1, 2025
ABVC BioPharma Strengthens Oncology Partnership With $100,000 Milestone Payment From OncoX BioPharma
July 24, 2025
ABVC BioPharma Records $100,000 Licensing Milestone From ForSeeCon, Strengthening Eye Health Program
July 18, 2025
ABVC BioPharma Receives $150K Milestone From AiBtl, Bringing Total Licensing Revenue to $846K Across Strategic Partnerships
July 10, 2025
ABVC BioPharma CEO Dr. Uttam Patil Recognized Among Elite Indian-Origin CEOs Making Global Impact in Science and Technology
June 26, 2025
ABVC BioPharma Converts Strategic Note Into Equity in AiBtl BioPharma; Commits to Up to $20 Million in Total Investment
June 24, 2025
ABVC BioPharma Expands Oncology Portfolio as Affiliate OncoX Acquires Patented Lycopenoid Platform Valued at $4.06 Million
June 6, 2025
ABVC BioPharma Announces Board Approval of Share Dividend Showing Confidence in Subsidiary Growth and Long-Term Shareholder Value
June 3, 2025
ABVC BioPharma Regains Nasdaq Minimum Bid Price Compliance
May 14, 2025
ABVC BioPharma Secures Japanese Patent for Its Natural MDD Treatment Candidate ABV-1504
May 9, 2025
ABVC BioPharma Announces First Quarter 2025 Financial Results and Strategic Planning for AI-Driven Agricultural Project in Taiwan
May 1, 2025
UPDATE: ABVC BioPharma Announces 2024 Financial Results
April 16, 2025
ABVC BioPharma Announces 2024 Financial Results
April 15, 2025
ABVC's Subsidiary AiBtl Signs Share-for-Land Agreement in Asia With Deal Valued at USD $7.67 Million
April 3, 2025
ABVC BioPharma Maintains Lucrative Global Licensing Agreements and Promising CDMO Acquisition, Strengthening Growth Potential
March 19, 2025
ABVC BioPharma Plans to Expand Investment in U.S. for Production Facilities and Products for Unmet Medical Needs
March 5, 2025
ABVC and BioLite Japan Implement Strategy to Advance Japan's Biotech Innovation Into Global Markets
February 26, 2025
ABVC BioPharma Announces Potential $7M Cash Licensing Income from Existing Agreements in 2025
February 20, 2025
ABVC BioPharma, Inc. Granted Additional 180-Day Grace Period to Regain Compliance With Nasdaq Bid Price Requirement
January 12, 2025